TY - JOUR
T1 - Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts
AU - Chee, Cheng E.
AU - Steensma, David P.
AU - Wu, Wenting
AU - Hanson, Curtis A.
AU - Tefferi, Ayalew
PY - 2008/8
Y1 - 2008/8
N2 - In a retrospective study of 126 adult patients with French-American- British-defined refractory anemia with ringed sideroblasts (RARS), staging by the International Prognostic Scoring System was highly predictive of survival outcome (P < 0.0001). In addition, red blood cell (RBC) transfusion requirement at diagnosis (P = 0.001), but not the number of RBC units transfused during the disease course (P = 0.17), was independently associated with inferior survival. There were no correlations between survival and serum ferritin level, measured either at diagnosis (median 567 ng/mL, range 16-3,475; P = 0.24) or during follow-up (median 1,108 ng/mL; range 238-43,500; P = 0.72). Similarly, there was no difference in survival when patients were stratified by serum ferritin levels of < or ≥ 1,000 ng/mL at diagnosis or peak serum ferritin levels of <1,000, 1,000-5,000, or >5,000 ng/mL during follow-up. The current study does not support the contention that transfusional hemosiderosis is an adverse prognostic factor in "good risk" myelodysplastic syndrome.
AB - In a retrospective study of 126 adult patients with French-American- British-defined refractory anemia with ringed sideroblasts (RARS), staging by the International Prognostic Scoring System was highly predictive of survival outcome (P < 0.0001). In addition, red blood cell (RBC) transfusion requirement at diagnosis (P = 0.001), but not the number of RBC units transfused during the disease course (P = 0.17), was independently associated with inferior survival. There were no correlations between survival and serum ferritin level, measured either at diagnosis (median 567 ng/mL, range 16-3,475; P = 0.24) or during follow-up (median 1,108 ng/mL; range 238-43,500; P = 0.72). Similarly, there was no difference in survival when patients were stratified by serum ferritin levels of < or ≥ 1,000 ng/mL at diagnosis or peak serum ferritin levels of <1,000, 1,000-5,000, or >5,000 ng/mL during follow-up. The current study does not support the contention that transfusional hemosiderosis is an adverse prognostic factor in "good risk" myelodysplastic syndrome.
UR - http://www.scopus.com/inward/record.url?scp=49149112388&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=49149112388&partnerID=8YFLogxK
U2 - 10.1002/ajh.21192
DO - 10.1002/ajh.21192
M3 - Article
C2 - 18442062
AN - SCOPUS:49149112388
SN - 0361-8609
VL - 83
SP - 611
EP - 613
JO - American journal of hematology
JF - American journal of hematology
IS - 8
ER -